



has the pleasure of inviting you to the conference:

The Multimorbidity Care Program

Detect. Manage. Prevent

with the participation of:

Dr. Lori-Ann Fisher
Consultant Nephrologist

Date: May 8, 2025
Time: 7:00 pm
Place: Zoom ([CLICK TO REGISTER](#))

TRIVERAM
atorvastatin perindopril amlodipine

TRIPLIXAM
perindopril indapamide amlodipine

COVERAM
perindopril amlodipine

NATRIXAM
indapamide amlodipine

PRETERAX
perindopril indapamide

COVERSYL
perindopril

NATRILIX SR
indapamide

Triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination. **Triplixam** is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level. **Coveram** is indicated as substitution therapy for treatment of essential hypertension and/or stable coronary artery disease, in patients already controlled with perindopril and amlodipine given concurrently at the same dose level. **Natrixam** is indicated as substitution therapy for treatment of essential hypertension in patients already controlled with indapamide and amlodipine given concurrently at the same dose level. **Preterax** 2.5/0.625: Essential hypertension. PRETERAX 5/1.25: Essential hypertension in patients whose blood pressure is not adequately controlled on perindopril alone. PRETERAX 10/2.5: Substitution therapy for treatment of essential hypertension in patients already controlled with perindopril and indapamide given concurrently at the same dose level. **Coversyl** 5mg is indicated for Treatment of hypertension, heart failure and stable coronary artery disease. Coversyl 10mg is indicated for Treatment of hypertension and stable coronary artery disease. **Natrilix** is indicated for patients with essential hypertension. **For complete information**, please refer to the Summary of Product Characteristics of your country. **In case of an adverse reaction** with these products, please inform: farmacovigilancia.centralamerica@servier.com. **SCAC 10/24 ME 123 HTA** - For the exclusive use of health care professionals. **SERVIER CENTRO AMÉRICA Y CARIBE S.A.**, Costa del Este, PH Dream Plaza, Piso 9, Panamá, República de Panamá.